GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » Total Receivables

Vidac Pharma Holding (STU:T9G) Total Receivables : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding Total Receivables?

Vidac Pharma Holding's Total Receivables for the quarter that ended in Jun. 2024 was €0.00 Mil.


Vidac Pharma Holding Total Receivables Historical Data

The historical data trend for Vidac Pharma Holding's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vidac Pharma Holding Total Receivables Chart

Vidac Pharma Holding Annual Data
Trend Dec21 Dec22 Dec23
Total Receivables
0.04 0.01 0.06

Vidac Pharma Holding Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Receivables Get a 7-Day Free Trial 0.01 0.01 0.01 0.06 -

Vidac Pharma Holding Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Vidac Pharma Holding Total Receivables Related Terms

Thank you for viewing the detailed overview of Vidac Pharma Holding's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Vidac Pharma Holding Business Description

Traded in Other Exchanges
N/A
Address
Wenlock Road, 20-22, London, GBR, N1 7GU
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines